logo
Despite historic indictment, doctors will keep mailing abortion pills across state lines

Despite historic indictment, doctors will keep mailing abortion pills across state lines

Yahoo08-05-2025
Packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023 in Rockville, Maryland. (Photo illustration by)
When the news broke on Jan. 31 that a New York physician had been indicted for shipping abortion medications to a woman in Louisiana, it stoked fear across the network of doctors and medical clinics who engage in similar work.
'It's scary. It's frustrating,' said Angel Foster, co-founder of the Massachusetts Medication Abortion Access Project, a clinic near Boston that mails mifepristone and misoprostol pills to patients in states with abortion bans. But, Foster added, 'it's not entirely surprising.'
Ever since the Supreme Court overturned Roe v. Wade in 2022, abortion providers like her had been expecting prosecution or another kind of legal challenge from states with abortion bans, she said.
'It was unclear when those tests would come, and would it be against an individual provider or a practice or organization?' she said. 'Would it be a criminal indictment, or would it be a civil lawsuit,' or even an attack on licensure? she wondered. 'All of that was kind of unknown, and we're starting to see some of this play out.'
The indictment also sparked worry among abortion providers like Kohar Der Simonian, medical director for Maine Family Planning. The clinic doesn't mail pills into states with bans, but it does treat patients who travel from those states to Maine for abortion care.
'It just hit home that this is real, like this could happen to anybody, at any time now, which is scary,' Der Simonian said.
Der Simonian and Foster both know the indicted doctor, Margaret Carpenter.
'I feel for her. I very much support her,' Foster said. 'I feel very sad for her that she has to go through all of this.'
On Jan. 31, Carpenter became the first U.S. doctor criminally charged for providing abortion pills across state lines — a medical practice that grew after the U.S. Supreme Court's Dobbs v. Jackson Women's Health Organization decision on June 24, 2022, which overturned Roe.
Since Dobbs, 12 states have enacted near-total abortion bans, and an additional 10 have outlawed the procedure after a certain point in pregnancy, but before a fetus is viable.
Louisiana officials lament loss of USDA money to help schools, food banks buy from local farmers
Carpenter was indicted alongside a Louisiana mother who allegedly received the mailed package and gave the pills prescribed by Carpenter to her minor daughter.
The teen wanted to keep the pregnancy and called 911 after taking the pills, according to an NPR and KFF Health News interview with Tony Clayton, the Louisiana local district attorney prosecuting the case. When police responded, they learned about the medication, which carried the prescribing doctor's name, Clayton said.
On Feb. 11, Louisiana's Republican governor, Jeff Landry, signed an extradition warrant for Carpenter. He later posted a video arguing she 'must face extradition to Louisiana, where she can stand trial and justice will be served.'
New York's Democratic governor, Kathy Hochul, countered by releasing her own video, confirming she was refusing to extradite Carpenter. The charges carry a possible five-year prison sentence.
'Louisiana has changed their laws, but that has no bearing on the laws here in the state of New York,' Hochul said.
Eight states — New York, Maine, California, Colorado, Massachusetts, Rhode Island, Vermont, and Washington — have passed laws since 2022 to protect doctors who mail abortion pills out of state, and thereby block or 'shield' them from extradition in such cases. But this is the first criminal test of these relatively new 'shield laws.'
In the Deep South, health care fights echo civil rights battles
The telemedicine practice of consulting with remote patients and prescribing them medication abortion via the mail has grown in recent years — and is now playing a critical role in keeping abortion somewhat accessible in states with strict abortion laws, according to research from the Society of Family Planning, a group that supports abortion access.
Doctors who prescribe abortion pills across state lines describe facing a new reality in which the criminal risk is no longer hypothetical. The doctors say that if they stop, tens of thousands of patients would no longer be able to end early pregnancies safely at home, under the care of a U.S. physician. But the doctors could end up in the crosshairs of a legal clash over the interstate practice of medicine when two states disagree on whether people have a right to end a pregnancy.
Maine Family Planning, a network of clinics across 19 locations, offers abortions, birth control, gender-affirming care, and other services. One patient recently drove over 17 hours from South Carolina, a state with a six-week abortion ban, Der Simonian said.
For Der Simonian, that case illustrates how desperate some of the practice's patients are for abortion access. It's why she supported Maine's 2024 shield law, she said.
Maine Family Planning has discussed whether to start mailing abortion medication to patients in states with bans, but it has decided against it for now, according to Kat Mavengere, a clinic spokesperson.
Reflecting on Carpenter's indictment, Der Simonian said it underscored the stakes for herself — and her clinic — of providing any abortion care to out-of-state patients. Shield laws were written to protect against the possibility that a state with an abortion ban charges and tries to extradite a doctor who performed a legal, in-person procedure on someone who had traveled there from another state, according to a review of shield laws by the Center on Reproductive Health, Law, and Policy at the UCLA School of Law.
'It is a fearful time to do this line of work in the United States right now,' Der Simonian said. 'There will be a next case.' And even though Maine's shield law protects abortion providers, she said, 'you just don't know what's going to happen.'
Data shows that in states with total or six-week abortion bans, an average of 7,700 people a month were prescribed and took mifepristone and misoprostol to end their pregnancies by out-of-state doctors practicing in states with shield laws. The data, covering the second quarter of 2024, is part of a #WeCount report estimating the volume and types of abortions in the U.S., conducted by the Society of Family Planning.
Among Louisiana residents, nearly 60% of abortions took place via telemedicine in the second half of 2023 (the most recent period for which estimates are available), giving Louisiana the highest rate of telemedicine abortions among states that passed strict bans after Dobbs, according to the #WeCount survey.
Louisiana considers 'homelessness courts' as housing advocates stress lack of resources
Organizations like the Massachusetts Medication Abortion Access Project, known as the MAP, are responding to the demand for remote care. The MAP was launched after the Dobbs ruling, with the mission of writing prescriptions for patients in other states.
During 2024, the MAP says, it was mailing abortion medications to about 500 patients a month. In the new year, the monthly average has grown to 3,000 prescriptions a month, said Foster, the group's co-founder.
The majority of the MAP's patients — 80% — live in Texas or states in the Southeast, a region blanketed with near-total abortion restrictions, Foster said.
But the recent indictment from Louisiana will not change the MAP's plans, Foster said. The MAP currently has four staff doctors and is hiring one more.
'I think there will be some providers who will step out of the space, and some new providers will step in. But it has not changed our practice,' Foster said. 'It has not changed our intention to continue to practice.'
The MAP's organizational structure was designed to spread potential liability, Foster said.
'The person who orders the pills is different than the person who prescribes the pills, is different from the person who ships the pills, is different from the person who does the payments,' she explained.
In 22 states and Washington, D.C., Democratic leaders helped establish shield laws or similarly protective executive orders, according to the UCLA School of Law review of shield laws.
The review found that in eight states, the shield law applies to in-person and telemedicine abortions. In the other 14 states plus Washington, D.C., the protections do not explicitly extend to abortion via telemedicine.
Most of the shield laws also apply to civil lawsuits against doctors. Over a month before Louisiana indicted Carpenter, Texas Attorney General Ken Paxton filed a civil suit against her. A Texas judge ruled against Carpenter on Feb. 13, imposing penalties of more than $100,000.
By definition, state shield laws cannot protect doctors when they leave the state. If they move or even travel elsewhere, they lose the first state's protection and risk arrest in the destination state, and maybe extradition to a third state.
Louisiana looks to RFK Jr. for school lunch guidelines, limits on SNAP purchases
Physicians doing this type of work accept there are parts of the U.S. where they should no longer go, said Julie F. Kay, a human rights lawyer who helps doctors set up telemedicine practices.
'There's really a commitment not to visit those banned and restricted states,' said Kay, who worked with Carpenter to help start the Abortion Coalition for Telemedicine.
'We didn't have anybody going to the Super Bowl or Mardi Gras or anything like that,' Kay said of the doctors who practice abortion telemedicine across state lines.
She said she has talked to other interested doctors who decided against doing it 'because they have an elderly parent in Florida, or a college student somewhere, or family in the South.' Any visits, even for a relative's illness or death, would be too risky.
'I don't use the word 'hero' lightly or toss it around, but it's a pretty heroic level of providing care,' Kay said.
Carpenter's case remains unresolved. New York's rebuff of Louisiana's extradition request shows the state's shield law is working as designed, according to David Cohen and Rachel Rebouché, law professors with expertise in abortion laws.
Louisiana officials, for their part, have pushed back in social media posts and media interviews.
'It is not any different than if she had sent fentanyl here. It's really not,' Louisiana Attorney General Liz Murrill told Fox 8 News in New Orleans. 'She sent drugs that are illegal to send into our state.'
Louisiana's next step would be challenging New York in federal courts, according to legal experts across the political spectrum.
NPR and KFF Health News asked Clayton, the Louisiana prosecutor who charged Carpenter, whether Louisiana has plans to do that. Clayton declined to answer.
A major problem with the new shield laws is that they challenge the basic fabric of U.S. law, which relies on reciprocity between states, including in criminal cases, said Thomas Jipping, a senior legal fellow with the Heritage Foundation, which supports a national abortion ban.
'This actually tries to undermine another state's ability to enforce its own laws, and that's a very grave challenge to this tradition in our country,' Jipping said. 'It's unclear what legal issues, or potentially constitutional issues, it may raise.'
But other legal scholars disagree with Jipping's interpretation. The U.S. Constitution requires extradition only for those who commit crimes in one state and then flee to another state, said Cohen, a law professor at Drexel University's Thomas R. Kline School of Law.
Telemedicine abortion providers aren't located in states with abortion bans and have not fled from those states — therefore they aren't required to be extradited back to those states, Cohen said. If Louisiana tries to take its case to federal court, he said, 'they're going to lose because the Constitution is clear on this.'
'The shield laws certainly do undermine the notion of interstate cooperation, and comity, and respect for the policy choices of each state,' Cohen said, 'but that has long been a part of American law and history.'
Louisiana senators face wrongful death lawsuit against nursing home they co-own
When states make different policy choices, sometimes they're willing to give up those policy choices to cooperate with another state, and sometimes they're not, he said.
The conflicting legal theories will be put to the test if this case goes to federal court, other legal scholars said.
'It probably puts New York and Louisiana in real conflict, potentially a conflict that the Supreme Court is going to have to decide,' said Rebouché, dean of the Temple University Beasley School of Law.
Rebouché, Cohen, and law professor Greer Donley worked together to draft a proposal for how state shield laws might work. Connecticut passed the first law — though it did not include protections specifically for telemedicine. It was signed by the state's governor in May 2022, over a month before the Supreme Court overturned Roe, in anticipation of potential future clashes between states over abortion rights.
In some shield-law states, there's a call to add more protections in response to Carpenter's indictment.
New York state officials have. On Feb. 3, Hochul signed a law that allows physicians to name their clinic as the prescriber — instead of using their own names — on abortion medications they mail out of state. The intent is to make it more difficult to indict individual doctors. Der Simonian is pushing for a similar law in Maine.
Samantha Glass, a family medicine physician in New York, has written such prescriptions in a previous job, and plans to find a clinic where she could offer that again. Once a month, she travels to a clinic in Kansas to perform in-person abortions.
Carpenter's indictment could cause some doctors to stop sending pills to states with bans, Glass said. But she believes abortion should be as accessible as any other health care.
'Someone has to do it. So why wouldn't it be me?' Glass said. 'I just think access to this care is such a lifesaving thing for so many people that I just couldn't turn my back on it.'
SUPPORT: YOU MAKE OUR WORK POSSIBLE
This article is from a partnership that includes WWNO, NPR, and KFF Health News. It first appeared on KFF Health News and is republished here under a Creative Commons license. KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF and subscribe to KFF Health News' free Morning Briefing.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gigatrends, AI, and the Future of Oncology Clinical Pathways to Take Center Stage at HMP Global's CPC+CBEx 2025
Gigatrends, AI, and the Future of Oncology Clinical Pathways to Take Center Stage at HMP Global's CPC+CBEx 2025

Associated Press

time5 hours ago

  • Associated Press

Gigatrends, AI, and the Future of Oncology Clinical Pathways to Take Center Stage at HMP Global's CPC+CBEx 2025

Renowned futurist and Delphi Group Chairman & Founder Thomas Koulopoulos to deliver keynote at national event held September 5-6 in Boston. 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.'— Thomas Koulopoulos, Delphi Group Founder & Chairman MALVERN, PA, UNITED STATES, August 15, 2025 / / -- Against a backdrop of rapid innovation and mounting complexity in oncology, the 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) will convene September 5–6 in Boston, Massachusetts. The event will bring together cancer care leaders, payers, and innovators to examine how major trends—artificial intelligence, emerging treatments, stakeholder collaboration, whole-person care, and workforce transformation—are reshaping the design and implementation of clinical pathways and value-based care strategies. Keynote speaker Thomas Koulopoulos will deliver keynote remarks, 'Navigating Tomorrow's Healthcare Gigatrends,' from 9:25 – 10:10 AM on September 5, exploring how healthcare organizations can evolve legacy models into adaptive, AI-supported systems. Koulopoulos is Chairman and Founder of Delphi Group, a 30-year-old Boston think tank named one of the fastest growing private companies by Inc. Magazine, a renowned author and inventor, and the founding partner of Acrovantage Ventures, which invests in early-stage technology startups. What is Clinical Pathways Congress + Cancer Care Business Exchange? The Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) is a national conference focused on the design, implementation, and evolution of oncology clinical pathways. The event brings together leaders across cancer care, policy, pharmaceutical innovation, and health systems to accelerate value-based care strategies, healthcare infrastructure solutions, and market access innovations that redefine oncology. 2025 Educational Program Highlights • AI-Enabled Pathways: Explore how artificial intelligence, real-time data, and digital tools are transforming pathway design and clinical decision-making in oncology. • Value-Based Oncology Care: Learn how evolving CMS policies and payment models are reframing cancer care economics—and how pathways can serve as strategic levers for value creation. • Collaborative Leadership: Attend panel sessions featuring oncologists, pharmacists, data scientists, health system executives, and policy advocates working to align clinical, operational, and financial priorities. • Real-World Tools for Implementation: Gain access to practical implementation toolkits and strategies showcased through high-impact, peer-reviewed programming—offering actionable insights to support frontline adoption of clinical pathways and drive measurable outcomes. Key Benefits of Attending • Understand how top cancer organizations combat staffing strain and burnout by leveraging AI, expanding roles, and building resilient models. • Join providers, payers, and pathway developers as they collaborate to accelerate pathway adoption and deliver optimal access assistance. • Gain insider perspectives from pathway developers and clinical leaders on how pharma can meaningfully engage to shape inclusion decisions. • Participate in curated B2B networking through the Cancer Care Business Exchange (CBEx). • Earn CME/CE credits while gaining practical, system-wide strategies. Thomas Koulopoulos on Gigatrends and the Future of Oncology • How AI and virtual health can create a continuous care loop: 'AI's pattern-recognition and virtual health's 'anywhere, anytime' reach fuse into a continuous care loop ... The prize: fewer cliff-edge hospitalizations and a seamless hand-off from prevention to acute to chronic management.' • Why clinical pathways are the lever for value over cost: 'When pathways are built around outcomes instead of encounters, they become the financial Rosetta Stone that translates 'spend' into 'health value.'' • The future of care systems: 'The next wave of healthcare won't reward those who build bigger hospitals or prettier dashboards—it will reward those who turn clinical pathways into adaptive, learning ecosystems.' Who Should Attend • Cancer center executives, innovation directors, and service line directors • Oncology operations and quality leaders • Pathway implementation managers and VBC strategists • Health economists, outcomes researchers, and market access teams • Consultants and digital health innovators Event details • Event: Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) • Dates: September 5–6, 2025 • Location: Boston, Massachusetts • Event Website About HMP Global HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit Sandi Beason, APR HMP Global [email protected] Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Costco says it's not selling the abortion pill mifepristone
Costco says it's not selling the abortion pill mifepristone

USA Today

time6 hours ago

  • USA Today

Costco says it's not selling the abortion pill mifepristone

Costco will not be adding the abortion pill mifepristone to its pharmacies. Confirming the news to Reuters on Thursday, Aug. 14, Costco said the company will not sell the pill due to low demand. USA TODAY has contacted Costco for more information on the decision, but the company told Reuters that, typically, patients get the drug from their doctors. Mifepristone is a drug that blocks a hormone needed to continue pregnancy, according to the U.S. Food and Drug Administration (FDA). According to the FDA, mifepristone is taken with another drug called misoprostol to terminate pregnancies up to 10 weeks from the first day of the last menstrual period. The medications are taken over the course of two days. Mifepristone first got FDA approval in September 2000 for medical termination of pregnancy through seven weeks gestation; this was extended to 10 weeks in 2016. The FDA approved a generic version of the drug in 2019, according to the agency's website. Costco's announcement comes at a time when religious activist groups are pushing back against abortion drugs. Arguments against abortion drug, lawsuit explained In November 2022, a group of anti-abortion medical professionals sued the FDA in Texas federal district court, challenging its approval of the drug as well as expanded access to it. In April 2023, the U.S. Supreme Court sided with the group and suspended the FDA's approval of mifepristone. The court later issued an order that allowed individuals to have access to mifepristone during the appeals process. The Supreme Court then ruled in June 2024 that the religious group's case was to be dismissed because the group did not have 'the necessary legal standing to bring this challenge in federal court in the first place,' according to the Johns Hopkins Bloomberg School of Public Health. According to legal experts such as Joanne Rosen, a practice professor in Health Policy and Management at Johns Hopkins, plaintiffs must prove they have been hurt by the practices they're arguing against and that the government or agency was at fault. 'The coalition of plaintiffs were anti-abortion physicians and an anti-abortion medical association,' Rosen previously said about the case. 'None of them prescribe mifepristone or perform abortions. None of them have been required by FDA action to do so.' According to Johns Hopkins, another group or plaintiff could file a lawsuit of their own with more concrete evidence. Retailers targeted as part of anti-abortion campaigns While some stores, such as Walgreens and CVS, have chosen to sell mifepristone, other retailers haven't clarified whether they'll sell it. USA TODAY has reached out to three of those retailers — Walmart, Albertson's, and McKesson — for comment. Walmart declined to comment. Albertson's and McKesson did not immediately respond. "Many retailers have become more cautious about taking overt political or social stances after recent controversies triggered boycotts, negative media coverage, and polarized consumer reactions," Arun Sundaram, senior analyst at the California Family Rights Act, told Reuters. Religious groups such as Inspire Investing have credited themselves with keeping pharmacies from selling the drug. In December 2024, Kroger and Sam's Club allegedly began selling mifepristone in their pharmacies then said the pills were listed on their pharmacy websites by mistake, according to the Wisconsin Family Council. The council called out CVS and Walgreens for still offering abortion pills at their pharmacies. The drug has been the focal point of multiple protests as pro-choice groups demand continued access to the drug. Have there been deaths linked to mifepristone? According to the FDA, there have been 36 reports of deaths in patients associated with the medication since September 2000. This includes two ectopic pregnancies, which is when the fetus grows outside the womb, and multiple cases of sepsis. 'The adverse events cannot with certainty be causally attributed to mifepristone because of concurrent use of other drugs, other medical or surgical treatments, co-existing medical conditions, and information gaps about patient health status and clinical management of the patient,' the FDA said on its website. Contributing: Reuters Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@

Costco to halt sale of abortion pill mifepristone at U.S. pharmacies
Costco to halt sale of abortion pill mifepristone at U.S. pharmacies

San Francisco Chronicle​

time6 hours ago

  • San Francisco Chronicle​

Costco to halt sale of abortion pill mifepristone at U.S. pharmacies

Costco will not dispense the abortion pill mifepristone at any of its more than 500 pharmacy locations in the United States, citing a lack of consumer demand. The decision, first reported by Bloomberg, followed months of pressure from conservative religious groups urging major retailers to avoid selling the drug. 'Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,' Costco said in a statement Thursday. The company declined to say whether lobbying efforts played a role. The move was welcomed by the Alliance Defending Freedom, a conservative legal advocacy group that has long campaigned against the drug's availability. 'We applaud Costco for doing the right thing by its shareholders and resisting activist calls to sell abortion drugs,' said Michael Ross, legal counsel for ADF, in a statement. 'They have nothing to gain and much to lose by becoming abortion dispensaries.' Mifepristone, approved by the Food and Drug Administration in 2000, is the first of two medications used to end a pregnancy within the first 10 weeks. It is now used in more than half of all abortions in the U.S., according to the Guttmacher Institute. CVS and Walgreens are currently the only national chains certified to dispense mifepristone under FDA guidelines, and only in states where abortion remains legal. 'The U.S. Supreme Court's ruling on mifepristone access allows Walgreens to continue to dispense mifepristone under the FDA guidelines,' Walgreens' website states.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store